<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with either type 1 or type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (DM) are predisposed to fragile fracture </plain></SENT>
<SENT sid="1" pm="."><plain>In particular, although bone mineral density in patients with type 2 DM is somewhat higher than control subjects, diabetic patients are more likely to break a bone </plain></SENT>
<SENT sid="2" pm="."><plain>Because the number of elderly patients with DM is getting larger, it is necessary to prevent fracture in those </plain></SENT>
<SENT sid="3" pm="."><plain>Unfortunately, substantial randomized control trials are yet to be done in patients with DM to clarify if anti-osteoporotic drugs are effective to prevent fractures </plain></SENT>
<SENT sid="4" pm="."><plain>According to post-hoc analyses of pivotal clinical studies of <z:chebi fb="0" ids="2567">alendronate</z:chebi> and <z:chebi fb="0" ids="8772">raloxifene</z:chebi>, best available clinical data at the present time, those anti-osteoporotic drugs seem to be equally effective in diabetic patients to controls </plain></SENT>
<SENT sid="5" pm="."><plain>We are now waiting for evidence of effects of teriparatide and other drugs on patients with DM </plain></SENT>
</text></document>